HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Protein-Tyrosine Kinases (Tyrosine Kinase)

Subscribe to New Research on Protein-Tyrosine Kinases

Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.

Also Known As:

Tyrosine Kinase; Protein-Tyrosine Kinase; Kinase, Tyrosine; Tyrosine Protein Kinases; Tyrosine-Specific Protein Kinases; Tyrosylprotein Kinase; Kinase, Protein-Tyrosine; Kinase, Tyrosine Protein; Kinase, Tyrosine-Specific Protein; Kinase, Tyrosylprotein; Kinases, Protein-Tyrosine; Kinases, Tyrosine Protein; Kinases, Tyrosine-Specific Protein; Protein Kinase, Tyrosine-Specific; Protein Kinases, Tyrosine; Protein Kinases, Tyrosine-Specific; Protein Tyrosine Kinase; Protein Tyrosine Kinases; Tyrosine Specific Protein Kinase; Tyrosine Specific Protein Kinases; Tyrosine Protein Kinase; Tyrosine-Specific Protein Kinase; ATP:protein-tyrosine O-phosphotransferase

Networked: 12167 relevant articles (840 outcomes, 1228 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes
- Enzymes: 34502
  - Transferases: 4296
    - Phosphotransferases: 30637
      - Phosphotransferases (Alcohol Group Acceptor)
        Protein Kinases: 9706
        Protein-Tyrosine Kinases: 12167
        anaplastic lymphoma kinase: 1167
        Focal Adhesion Protein-Tyrosine Kinases: 974
        src-Family Kinases: 407
        Receptor Protein-Tyrosine Kinases: 401
        Bcr-Abl tyrosine kinase: 350
        Syk kinase: 202
        Mitogen-Activated Protein Kinase Kinases: 196
        Agammaglobulinaemia tyrosine kinase: 137
        Janus Kinases: 102
        protein-tyrosine kinase c-src: 83
        insulin receptor tyrosine kinase: 79
        Dyrk kinase: 29
        p80(NPM-ALK) protein: 25
        ZAP-70 Protein-Tyrosine Kinase: 19
        emt protein-tyrosine kinase: 18
        Tec protein-tyrosine kinase: 11
        FAK-related nonkinase: 9
        proto-oncogene protein c-fes-fps: 9
        ARG tyrosine kinase: 4
        Proto-Oncogene Proteins c-abl: 2
        Proto-Oncogene Proteins c-fes: 1
        PTK72: 1
        Arabidopsis ADK1 protein
        Arabidopsis APK1A protein
        Avian sarcoma virus Y73 v-yes protein
        Bacteria WZC protein
        C elegans Ack-related tyrosine kinase-1
        C elegans FRK-1 protein
        C elegans MBK-2 protein
        C elegans OLD-1 protein
        C elegans Old-2 protein
        C elegans Scd-2 protein
        C elegans TPA-1 protein
        C elegans wee-1.3 protein
        Cdc42-associated tyrosine kinase 2
        Cdc42Hs-associated kinase
        Chlamydomonas reinhardtii SksC protein
        Clk dual-specificity kinases
        Dictyostelium discoideum SplA protein
        Drosophila abelson protein
        Drosophila Ack protein
        Drosophila breathless protein
        Drosophila Btk29A protein
        Drosophila doughnut protein
        Drosophila heartless protein
        Drosophila Shark protein
        Drosophila Src64B protein
        Drosophila Wee1 protein
        E coli Etk protein
        E coli wzc protein
        emb protein-tyrosine kinase
        Feline sarcoma virus v-fgr protein
        Fujinami sarcoma virus v-fps oncogene protein
        fyk kinase
        Gallus gallus sea protein
        Geodia cydonium receptor protein-tyrosine phosphatase
        gtk kinase
        human AATK protein
        human ACK1 protein
        human ACK2 protein
        human BMX protein
        human CDC42BPB protein
        human CSK protein
        human DYRK3 protein
        human FRK protein
        human PKMYT1 protein
        human PTK6 protein
        human RB1CC1 protein
        human ret-PTC fusion oncoproteins
        human ROS1 protein
        human TEL-ABL fusion protein
        human TEL-JAK1 protein
        human TEL-JAK3 protein
        human TEL-TYK2 protein
        human TNK1 protein
        human TWF1 protein
        human WEE1 protein
        human Wee1b protein
        Hydra attenuata HTK16 protein
        Hydra vulgaris Hinterteil protein
        mouse A6 protein
        mouse Aatk protein
        mouse Bmx protein
        mouse Kos1 protein
        mouse Ntrk2 protein
        mouse Ptk9l protein
        mouse Ret-Ptc1 oncoprotein
        mouse Tnk2 protein
        mouse Wee1 protein
        mouse Wee1B protein
        Nicotiana tabacum PK12 protein
        protein tyrosine kinase Pyk2-H
        rat ACK1 protein
        rat Bmx protein
        rat lynA protein
        rat lynB protein
        rat Matk protein
        rat Myt1 kinase
        rat RET-PTC oncoprotein
        rat Tec protein

Experts

1.	Cortes, Jorge: 98 articles (12/2015 - 09/2003)
2.	Kantarjian, Hagop: 79 articles (12/2015 - 03/2003)
3.	Jabbour, Elias: 56 articles (12/2015 - 11/2006)
4.	Jänne, Pasi A: 52 articles (12/2015 - 01/2003)
5.	Pao, William: 50 articles (02/2015 - 02/2004)
6.	Mitsudomi, Tetsuya: 48 articles (01/2016 - 10/2003)
7.	O'Brien, Susan: 47 articles (11/2015 - 09/2003)
8.	Kantarjian, Hagop M: 46 articles (10/2015 - 05/2002)
9.	Baccarani, Michele: 46 articles (09/2015 - 06/2003)
10.	Zhang, Li: 46 articles (09/2015 - 05/2004)

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/01/2009 - "The EGFR has been targeted through the development of selective tyrosine kinase inhibitors (TKIs) that have proven effective in a subset of non-small cell lung cancer (NSCLC) patients, many bearing gain-of-function EGFR mutations or egfr gene amplification. " 01/01/2014 - "This type of non-small-cell lung carcinoma more frequently involves EGFR gene abnormalities, which determine the efficacy of EGFR tyrosine kinase inhibitor therapies (EGFR TKIs). " 01/01/2015 - "Tyrosine kinase inhibitors (TKIs) against EGFR and c-Met are initially effective when administered individually or in combination to non-small cell lung cancer (NSCLC) patients. " 04/01/2014 - "[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]." 01/01/2015 - "EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR mutations, based on seven prospective randomized Phase III trials. "
2.	Neoplasms (Cancer) 06/01/2015 - "Given that tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with chronic myeloid leukaemia (CML), we were interested in examining the possible risk of long-term adverse events, such as the emergence of other neoplasms. " 02/01/2015 - "Cutaneous reactions, one of the most frequently observed adverse effects associated with tyrosine kinase inhibitors, can significantly affect patients' quality of life and drug adherence and represent a major therapeutic challenge to maximizing the efficacy of targeted cancer therapy. " 02/01/2014 - "Targeting EGFR with tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, progression-free survival (PFS), and quality of life. " 09/01/2014 - "Regorafenib, an orally available multitargeted tyrosine kinase inhibitor with antiangiogenic activity, has also demonstrated preclinical evidence of activity against a number of solid tumors and further studies have proven it to be effective in GISTs following failure of standard therapy, with manageable toxicity profile. " 02/28/2015 - "In tumors with activating EGFR mutations, tyrosine kinase inhibitors (TKI) are indicated as first-line treatment, although restricted to a very small target population. "
3.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/01/2015 - "Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the outcome of chronic myelogenous leukemia in the chronic phase (CML-CP). " 02/01/2015 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the clinical outcomes of patients with chronic myeloid leukemia (CML) in the chronic phase. " 10/01/2014 - "The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment. " 06/01/2014 - "The treatment of chronic myeloid leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKIs) is highly effective in reducing disease burden and prolonging overall survival in the majority of patients. " 05/01/2014 - "Treatment of chronic myeloid leukemia has been revolutionized by the development of oral tyrosine kinase inhibitors that are highly effective in managing the disease when taken consistently. "
4.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2013 - "Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC). " 08/01/2012 - "Tyrosine kinase inhibitors (TKIs) have dramatically improved the outcome of renal cell carcinoma (RCC) patients. " 02/10/2012 - "Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. " 02/10/2012 - "Complete remission with tyrosine kinase inhibitors in renal cell carcinoma." 12/01/2013 - "Although targeted therapies (ie, tyrosine kinase inhibitors and antiangiogenesis agents) are effective as first-line treatment of metastatic renal cell carcinoma (mRCC), moderate-to-severe adverse events have been reported in clinical trials of these agents. "
5.	Lung Neoplasms (Lung Cancer) 01/01/2009 - "Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. " 08/01/2011 - "Upfront tyrosine kinase inhibitor (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. " 10/01/2011 - "Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. " 07/26/2011 - "Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors." 01/01/2011 - "We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. "

Related Drugs and Biologics

1.	Epidermal Growth Factor Receptor (EGF Receptor)
2.	imatinib (Gleevec)
3.	gefitinib (Iressa)
4.	erlotinib (CP 358,774)
5.	sunitinib (Sutent)
6.	sorafenib (BAY 43-9006)
7.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
8.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
9.	lapatinib (GW572016)
10.	Phosphotransferases (Kinase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Radiotherapy
4.	Therapeutics
5.	Transplants (Transplant)